These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24657093)

  • 1. Structure-guided analysis of the human APOBEC3-HIV restrictome.
    Aydin H; Taylor MW; Lee JE
    Structure; 2014 May; 22(5):668-84. PubMed ID: 24657093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.
    Siu KK; Sultana A; Azimi FC; Lee JE
    Nat Commun; 2013; 4():2593. PubMed ID: 24185281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
    Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.
    Azimi FC; Lee JE
    Protein Sci; 2020 Feb; 29(2):391-406. PubMed ID: 31518043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing the Catalytic Deamination Activity of APOBEC3C Is Insufficient to Inhibit Vif-Deficient HIV-1.
    Jaguva Vasudevan AA; Hofmann H; Willbold D; Häussinger D; Koenig BW; Münk C
    J Mol Biol; 2017 Apr; 429(8):1171-1191. PubMed ID: 28315663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation.
    Bennett RP; Salter JD; Smith HC
    Trends Mol Med; 2018 May; 24(5):507-520. PubMed ID: 29609878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3 proteins and reverse transcription.
    Aguiar RS; Peterlin BM
    Virus Res; 2008 Jun; 134(1-2):74-85. PubMed ID: 18262674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A computational analysis of the structural determinants of APOBEC3's catalytic activity and vulnerability to HIV-1 Vif.
    Shandilya SM; Bohn MF; Schiffer CA
    Virology; 2014 Dec; 471-473():105-16. PubMed ID: 25461536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression.
    Kim DY; Kwon E; Hartley PD; Crosby DC; Mann S; Krogan NJ; Gross JD
    Mol Cell; 2013 Feb; 49(4):632-44. PubMed ID: 23333304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
    Albin JS; Harris RS
    Expert Rev Mol Med; 2010 Jan; 12():e4. PubMed ID: 20096141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
    Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
    Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of molecular attributes that influence LINE-1 restriction by all seven human APOBEC3 proteins.
    Renner TM; Bélanger K; Goodwin LR; Campbell M; Langlois MA
    Virology; 2018 Jul; 520():127-136. PubMed ID: 29860216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins.
    Virgen CA; Hatziioannou T
    J Virol; 2007 Dec; 81(24):13932-7. PubMed ID: 17942564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches.
    Richards C; Albin JS; Demir Ö; Shaban NM; Luengas EM; Land AM; Anderson BD; Holten JR; Anderson JS; Harki DA; Amaro RE; Harris RS
    Cell Rep; 2015 Dec; 13(9):1781-8. PubMed ID: 26628363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New World feline APOBEC3 potently controls inter-genus lentiviral transmission.
    Konno Y; Nagaoka S; Kimura I; Yamamoto K; Kagawa Y; Kumata R; Aso H; Ueda MT; Nakagawa S; Kobayashi T; Koyanagi Y; Sato K
    Retrovirology; 2018 Apr; 15(1):31. PubMed ID: 29636069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins.
    Jónsson SR; Haché G; Stenglein MD; Fahrenkrug SC; Andrésdóttir V; Harris RS
    Nucleic Acids Res; 2006; 34(19):5683-94. PubMed ID: 17038330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CBFß and HIV Infection.
    Kim DY; Gross JD
    Adv Exp Med Biol; 2017; 962():415-431. PubMed ID: 28299671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-linked glycosylation protects gammaretroviruses against deamination by APOBEC3 proteins.
    Rosales Gerpe MC; Renner TM; Bélanger K; Lam C; Aydin H; Langlois MA
    J Virol; 2015 Feb; 89(4):2342-57. PubMed ID: 25505062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of antagonism of human APOBEC3F by HIV-1 Vif.
    Hu Y; Desimmie BA; Nguyen HC; Ziegler SJ; Cheng TC; Chen J; Wang J; Wang H; Zhang K; Pathak VK; Xiong Y
    Nat Struct Mol Biol; 2019 Dec; 26(12):1176-1183. PubMed ID: 31792451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.